Pharmaceutical News

RSS

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

Acetaminophen overdose survivors have lower overall health following acute liver failure

Spontaneous survivors of acetaminophen overdose have significantly lower overall health compared to survivors or transplant recipients following acute liver failure caused by non-drug induced liver injury according to a new study published online in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

10 Jul 2013

UBC researchers develop vaccine to halt spread of West Nile Virus in birds

University of British Columbia researchers have developed a vaccine that may halt the spread of West Nile Virus among common and endangered bird species.

10 Jul 2013

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries).

10 Jul 2013

AOSSM presents awards and grants to encourage research in orthopaedic sports medicine

In order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine (AOSSM) will present ten research awards and seven grants during its Annual Meeting, July 11-14 in Chicago, IL.

10 Jul 2013

Researchers discover new class of antimalarial compounds

Despite renewed global efforts for eradication, malaria continues to exert devastating effects on human health. An estimated 220 million people are infected each year by malaria-causing Plasmodium parasites, which are transmitted by the bite of an infected mosquito. This enormous infection burden leads to some 660,000 lives lost to malaria each year, the majority of these young children in sub-Saharan Africa. While a vaccine to prevent malaria remains elusive, we depend on antimalarial compounds both to treat infections and prevent disease.

10 Jul 2013

Immunocore, GSK partner for cancer targeting ImmTACs

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Duchesnay USA today announced that Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy, more commonly known as morning sickness, is now available for coverage under the state and federal Medicaid program effective July 1st, 2013.

9 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Epanova™ for the treatment for patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500mg/dL).

9 Jul 2013

A few clinics are focused on helping pregnant women with prescription drug addictions

The Wall Street Journal examines the growing number of women addicted to pain killers and efforts to help them through pregnancies.

9 Jul 2013

ERC awards grants to boost research on vaccines

Vaccination has achieved huge success in controlling many devastating infectious diseases. However, there are still many such diseases, or 'pathogens', against which we cannot generate life-long protective immunity.

9 Jul 2013

Drugs used to control BP associated with lower risk of heart failure in diabetic patients

Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal).

9 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

COTI-2 is a computer-designed small molecule that was discovered by our artificial intelligence drug discovery platform called CHEMSAS.

8 Jul 2013

Hemp signs distribution agreement with CleanPath for new memory enhancing nutraceutical

Hemp, Inc. announces its first $200,000 sale after inking an exclusive agreement with CleanPath Resources Corp. This agreement is for CleanPath to distribute Hemp, Inc.'s life-changing nutraceutical, "Focus", which is designed to support "Clearer Thinking" and "Improve Memory".

8 Jul 2013

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the Company has been granted market access by the Italian Medicines Agency for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).

8 Jul 2013

Betaine boosts athletic performance by nearly 6%, study finds

According to a study supervised by Ithaca College's Exercise and Sport Sciences Chair Thomas Swensen, betaine—a nutrient found in shellfish and beets—boosts athletic performance by nearly six percent when added to a sports drink.

6 Jul 2013

Bioniche, Paladin close debt refinancing agreement and sign first licensing deal for Urocidin

Bioniche Life Sciences Inc. and Paladin Labs Inc. today announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin.

6 Jul 2013

Pharmaceutical News

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Acetaminophen overdose survivors have lower overall health following acute liver failure

UBC researchers develop vaccine to halt spread of West Nile Virus in birds

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

AOSSM presents awards and grants to encourage research in orthopaedic sports medicine

Researchers discover new class of antimalarial compounds

Immunocore, GSK partner for cancer targeting ImmTACs

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

A few clinics are focused on helping pregnant women with prescription drug addictions

ERC awards grants to boost research on vaccines

Drugs used to control BP associated with lower risk of heart failure in diabetic patients

Soligenix announces personalized medicine collaboration with SciClone

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

Hemp signs distribution agreement with CleanPath for new memory enhancing nutraceutical

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Betaine boosts athletic performance by nearly 6%, study finds

Bioniche, Paladin close debt refinancing agreement and sign first licensing deal for Urocidin

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News